Navigation Links
UK Must Maintain its Momentum in Stem Cell Expertise
Date:1/19/2009

LONDON, January 19 /PRNewswire/ -- Excalibur, the international investment house specialising in medical sciences, said today the UK must 'maintain its momentum' to deliver pioneering stem cell treatments if it is to remain at the forefront of medical technology.

Professor Sir Christopher Evans, founder and chairman of Excalibur, welcomed the announcement that ReNeuron plc has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a first-in-man clinical trial for the treatment of patients who have been left disabled by an ischaemic stroke.

Sir Christopher said: "We founded ReNeuron with Dr John Sinden and have invested in the company every step of the way for the last 10 years. We are proud the company has now reached this important milestone in its development of cell therapy treatment for stroke. There have been many scientific and financial hurdles to overcome during these years but we were determined to see this through.

"It is absolutely essential that we in the UK maintain our momentum in stem cell development and our belief in our ability to deliver these potentially revolutionary treatments. Too often in this country there is a tendency to focus on potentially negative outcomes but today's announcement is extremely important news for victims of stroke. At the end of the day lives - and the future of medicine in this area -- could be transformed by this science."

NOTES TO EDITORS

About Excalibur

Excalibur was launched in April 2008 following the acquisition of MVIL by Merlin Biosciences. Excalibur, which has a team of ten professionals, provides a wide range of investment and advisory services to the medical sciences sector. Its latest fund, Merlin Fund III, has successfully invested in a wide range of healthcare and medical sciences companies including PIramed which was sold for $185m in May 2008. Excalibur intends to replicate this successful investment strategy in the new funds that it is proposing to launch over the next 12 months.

Merlin originally founded ReNeuron in 1998 and has provided funding for the company over the last 10 years through Merlin 's Fund l and ll and has continued to invest in and support the company.

Further information: Ramsay Smith, Media House, +44(0)207-397-8459, Email:ramsay@mediahouse.co.uk, mobile +44(0)7788-414856.


'/>"/>
SOURCE Excalibur
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
2. Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained With Naproxen Sodium
3. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
4. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
5. Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
6. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
7. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... for the second quarter ending June 30, 2017. ... advanced stages of preparing for our pivotal Phase 3 ... Chaim Lebovits , President and Chief Executive Officer ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... third quarter of 2017. ... on or about October 27, 2017 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 18, 2017 , ... Mediaplanet today announces the launch of ... and highlighting the importance of proactive eye and ear health. The campaign focuses ... innovations in hearing aid technology. , In this issue, the American Speech-Language-Hearing ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, ... new charity drive to generate community support for efforts to educate the local population ... treatments for all types of cancer. , Each day in America, roughly 4,600 ...
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & ... assistance to communities in North-Central West Virginia, is embarking on a cooperative charity ... in the area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... planning assistance that serves communities throughout southern Florida, is working to support the ... assets to children from low income families. , The Take Stock In Children ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning firm that serves residential and commercial clients in the greater ... drive to raise community support for the fight against cancer. , Founded by ...
Breaking Medicine News(10 mins):